Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
A phase 2 trial of Bevacizumab, Lenvatinib, Rilvegostomig in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer is a phase 2 interventional study registered as NCT05775159 by AstraZeneca, with 294 participants planned, started 2023-04-24 and due to reach its primary completion in 2026-10-27. Interventions recorded: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Shares Rilvegostomig, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Rilvegostomig, Gemcitabine, Cisplatin, AstraZeneca.
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Lenvatinib, AstraZeneca, Hepatocellular carcinoma.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Shares Gemcitabine, Bevacizumab, Cisplatin.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Rilvegostomig, Cisplatin, AstraZeneca.